Form 6-K Telix Pharmaceuticals For: Sep 14

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. PINS
4. COIN
5. RDDT
6. FSLR
7. FND
8. SYK
9. GILD
10. SNDK

September 14, 2026 4:53 PM EDT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of September, 2026
 
Commission File Number: 001-42128
 
Telix Pharmaceuticals Limited
(Translation of registrant’s name into English)
 
55 Flemington Road
North Melbourne, Victoria 3051, Australia
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or
Form 40-F.
 
Form 20-F ☒ Form 40-F ☐
 
 
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
 
On September 14, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement
with the Australian Securities Exchange titled “FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara,”
a copy of which is attached to this Form 6-K as Exhibit 99.1.
Press release – September 14, 2026
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Telix Pharmaceuticals Limited
Date
:
September 14, 2026
By:
/s/ Christian Krautkramer
Name: Christian Krautkramer
Title: Group General Counsel
 
 
 
 

ATTACHMENTS / EXHIBITS

EX-99.1


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings